$700 Million is the total value of ARCH Venture Management, LLC's 8 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PULM | Exit | PULMATRIX, INC. | $0 | – | -43,639 | -100.0% | -0.00% | – |
| NTRA | Exit | NATERA, INC. | $0 | – | -32,098 | -100.0% | -0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2022-05-27
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| RUBIUS THERAPEUTICS, INC. | 12 | Q3 2022 | 65.5% |
| EQRX, INC. | 8 | Q3 2023 | 52.4% |
| ERASCA, INC. | 8 | Q3 2023 | 18.8% |
| VERVE THERAPEUTICS, INC. | 8 | Q3 2023 | 23.3% |
| CHIASMA INC | 8 | Q3 2020 | 25.7% |
| SINGULAR GENOMICS SYSTEMS, INC. | 8 | Q3 2023 | 4.6% |
| KURA ONCOLOGY INC | 7 | Q2 2020 | 27.6% |
| KARUNA THERAPEUTICS, INC. | 6 | Q1 2023 | 52.8% |
| DENALI THERAPEUTICS, INC. | 6 | Q3 2023 | 28.6% |
| SYROS PHARMACEUTICALS INC | 5 | Q3 2020 | 43.8% |
View ARCH Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-15 |
| 13F-HR/A | 2022-05-27 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
View ARCH Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.